Abstract
The Editors, to underline the need for more clinical research in Behcet syndrome (BS), discuss, among surely many, some areas in which more work is needed. In this line, we like to draw the readers’ attention to subspecialty-based disease/classification criteria, a prospective approach to give more sound causality aspect to the gene associations we already know, more both clinical and basic science work on the venous wall which recent data indicate is probably quite important in pathogenesis, and reassess the efficacy of drugs we currently use by withdrawal randomized clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ohno S, Aoki K, Sugiura S, et al. HL-A5 and Behçet’s disease. Lancet. 1973;2(7842):1383–4.
Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behçet’s syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34:244–6.
Madanat WY, Alawneh KM, Smadi MM, et al. The prevalence of Behçet’s disease in the north of Jordan: a hospital-based epidemiological survey. Clin Exp Rheumatol. 2017;35 Suppl 108:S51–4.
National Institutes of Health. All of us research program. https://www.joinallofus.org/. Accessed 30 Apr 2019.
Masatlioglu S, Seyahi E, Tahir Turanli E, et al. A twin study in Behçet’s syndrome. Clin Exp Rheumatol. 2010;28(Suppl 60):S62–6.
Karaca M, Hatemi G, Sut N, Yazici H. The papulopustular lesion/arthritis cluster of Behçet’s syndrome also clusters in families. Rheumatology (Oxford). 2012;51:1053–60.
Guedes-Barbosa LS. Oral and genital ulcers in Behçet’s disease. N Engl J Med. 2019;380:e7.
Yazici H, Seyahi E, Hatemi G, et al. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.
Yazici H, Yazici Y. Criteria for Behçet’s disease with reflections on all disease criteria. J Autoimmun. 2014;48-49:104–7.
Yazici H, Yazici Y. Diagnosis and/or classification of vasculitis: different? Curr Opin Rheumatol. 2016;28:3–7.
Fries JF, Hochberg MC, Medsger TA Jr, et al. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1994;37:454–62.
Yazici H. Diagnostic versus classification criteria – a continuum. Bull NYU Hosp Jt Dis. 2009;67:206–8.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.
Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013;21:337–50.
Seyahi E, Gjoni M, Durmaz EŞ, et al. Increased vein wall thickness in Behçet disease. J Vasc Surg Venous Lymphat Disord. 2019;7:677–84.
Ambrose N, Pierce IT, Gatehouse PD, et al. Magnetic resonance imaging of vein wall thickness in patients with Behcet’s syndrome. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S99–102.
Alibaz-Oner F, Ergelen R, Mutis A et al. Venous vessel wall thickness in lower extremity is increased in male Behcet’s disease patients. Clin Rheumatol. 2019;38(5):1447–1451.
Ugurlu S, Seyahi E, Yazici H. Prevalence of angina, myocardial infarction and intermittent claudication assessed by Rose Questionnaire among patients with Behcet’s syndrome. Rheumatology (Oxford). 2008;47:472–5.
Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.
Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402.
Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686–92.
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542–9.
Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69:2380–5.
Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology. 2018;125(9):1444–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yazici, Y., Seyahi, E., Hatemi, G., Yazici, H. (2020). A Few Suggestions for Further Research. In: Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H. (eds) Behçet Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-24131-5_22
Download citation
DOI: https://doi.org/10.1007/978-3-030-24131-5_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24130-8
Online ISBN: 978-3-030-24131-5
eBook Packages: MedicineMedicine (R0)